William Blair Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)

William Blair analyst Tim Lugo maintained a Buy rating on SAGE Therapeutics (SAGE) on November 30. The company’s shares closed last Friday at $71.00.

According to TipRanks.com, Lugo is a 5-star analyst with an average return of 16.5% and a 49.0% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Adamas Pharmaceuticals, and Revance Therapeutics.

Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $85.60, which is a 20.1% upside from current levels. In a report issued on November 16, Merrill Lynch also maintained a Buy rating on the stock with a $95.00 price target.

See today’s analyst top recommended stocks >>

SAGE Therapeutics’ market cap is currently $3.64B and has a P/E ratio of -7.00. The company has a Price to Book ratio of 5.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts